CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade X4 Pharmaceuticals, Inc. - XFOR CFD

0.83
1.19%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.84
Open 0.84
1-Year Change -52.54%
Day's Range 0.82 - 0.85
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 25, 2024 0.83 0.01 1.22% 0.82 0.87 0.79
Jul 24, 2024 0.81 0.02 2.53% 0.79 0.84 0.77
Jul 23, 2024 0.80 0.04 5.26% 0.76 0.82 0.74
Jul 22, 2024 0.76 0.04 5.56% 0.72 0.77 0.70
Jul 19, 2024 0.73 0.00 0.00% 0.73 0.73 0.70
Jul 18, 2024 0.72 0.00 0.00% 0.72 0.74 0.70
Jul 17, 2024 0.71 -0.02 -2.74% 0.73 0.75 0.69
Jul 16, 2024 0.73 0.05 7.35% 0.68 0.77 0.68
Jul 15, 2024 0.69 0.02 2.99% 0.67 0.69 0.66
Jul 12, 2024 0.67 0.01 1.52% 0.66 0.73 0.66
Jul 11, 2024 0.66 0.06 10.00% 0.60 0.67 0.58
Jul 10, 2024 0.58 -0.01 -1.69% 0.59 0.62 0.56
Jul 9, 2024 0.57 0.01 1.79% 0.56 0.59 0.54
Jul 8, 2024 0.56 0.02 3.70% 0.54 0.59 0.53
Jul 5, 2024 0.52 -0.03 -5.45% 0.55 0.55 0.51
Jul 3, 2024 0.52 -0.02 -3.70% 0.54 0.58 0.51
Jul 2, 2024 0.52 -0.04 -7.14% 0.56 0.56 0.51
Jul 1, 2024 0.56 -0.02 -3.45% 0.58 0.62 0.55
Jun 28, 2024 0.55 -0.12 -17.91% 0.67 0.67 0.55
Jun 27, 2024 0.64 -0.22 -25.58% 0.86 0.86 0.61

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

X4 Pharmaceuticals, Inc. Company profile

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, X4 Pharmaceuticals Inc revenues decreased from $3M to $0K. Net loss applicable to common stockholders increased 65% to $102.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $47.9M (expense).

Industry: Biotechnology & Medical Research (NEC)

61 North Beacon Street
4th Floor
BOSTON
MASSACHUSETTS 02134
US

People also watch

XRP/USD

0.61 Price
+1.640% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

67,928.50 Price
+3.990% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,029.00 Price
+1.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,281.07 Price
+4.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading